US Patent

US12268696 — Ganaxolone for use in treating tuberous sclerosis complex and seizure disorders

Method of Use · Assigned to Marinus Pharmaceuticals Inc · Expires 2042-09-30 · 16y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects the use of ganaxolone or a pharmaceutically acceptable salt thereof for treating tuberous sclerosis complex and epilepsy disorders.

USPTO Abstract

The disclosure to methods for treating tuberous sclerosis complex and epilepsy disorders comprising administering to a subject in need thereof a therapeutically effective amount of ganaxolone or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

Ztalmy (GANAXOLONE) · Marinus

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-3374`	—	Ztalmy

Patent Metadata

Patent number: US12268696
Jurisdiction: US
Classification: Method of Use
Expires: 2042-09-30
Drug substance claim: No
Drug product claim: No
Assignee: Marinus Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.